Cardiac uses of phosphodiesterase-5 inhibitors

Journal of the American College of Cardiology

Volumn 59, Issue 1, 2012, Pages 9-15

  Schwartz, Bryan G ^a   Levine, Laurence A ^b   Comstock, Gary ^c   Stecher, Vera J ^c   Kloner, Robert A ^a,d  

^a GOOD SAMARITAN HOSPITAL   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c PFIZER INC   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

altitude sickness; cardioprotection; heart failure; high altitude pulmonary edema; high altitude pulmonary hypertension; pulmonary hypertension; Raynaud's phenomenon; vasodilation

Indexed keywords

AMLODIPINE; BOSENTAN; CYCLIC GMP; DOXORUBICIN; ISOSORBIDE MONONITRATE; NIFEDIPINE; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROTEIN BCL 2; RHO KINASE; SILDENAFIL; SUPEROXIDE DISMUTASE; TADALAFIL; VARDENAFIL;

ARTICLE; BLOOD VESSEL TONE; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DIGITAL ULCER; DRUG EFFICACY; DRUG MECHANISM; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HIGH ALTITUDE PULMONARY EDEMA; HIGH ALTITUDE PULMONARY HYPERTENSION; HUMAN; HYPERTENSION; HYPOTENSION; LIMB ISCHEMIA; LUNG EDEMA; NONHUMAN; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; ULCER; UNSPECIFIED SIDE EFFECT;

EID: 84055182545     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.07.051     Document Type: Review

References (54)

1. B.G. Schwartz, R.A. Kloner Drug interactions with phosphodiesterase-5 inhibitors used for the treatment of erectile dysfunction or pulmonary hypertension Circulation 122 2010 88 95
2. S.L. Archer, E.D. Michelakis Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension N Engl J Med 361 2009 1864 1871
3. E.A. Bocchi, G. Guimaraes, A. Mocelin, F. Bacal, G. Bellotti, J.F. Ramires Sildenafil effects on exercise, neurohormonal activation, and erectile dysfunction in congestive heart failure: a double-blind, placebo-controlled, randomized study followed by a prospective treatment for erectile dysfunction Circulation 106 2002 1097 1103 (Pubitemid 34970850)
4. G.D. Lewis, R. Shah, K. Shahzad Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension Circulation 116 2007 1555 1562 (Pubitemid 47511419)
5. K. Hirata, A. Adji, C. Vlachopoulos, M.F. O'Rourke Effect of sildenafil on cardiac performance in patients with heart failure Am J Cardiol 96 2005 1436 1440 (Pubitemid 41566628)
6. L.J. Webster, E.D. Michelakis, T. Davis, S.L. Archer Use of sildenafil for safe improvement of erectile function and quality of life in men with New York Heart Association classes II and III congestive heart failure: a prospective, placebo-controlled, double-blind crossover trial Arch Intern Med 164 2004 514 520 (Pubitemid 38314447)
7. A. Behling, L.E. Rohde, F.C. Colombo, L.A. Goldraich, R. Stein, N. Clausell Effects of 5'-phosphodiesterase four-week long inhibition with sildenafil in patients with chronic heart failure: a double-blind, placebo-controlled clinical trial J Card Fail 14 2008 189 197 (Pubitemid 351444866)
8. M. Guazzi, M. Samaja, R. Arena, M. Vicenzi, M.D. Guazzi Long-term use of sildenafil in the therapeutic management of heart failure J Am Coll Cardiol 50 2007 2136 2144 (Pubitemid 350117342)
9. V. Melenovsky, H. Al-Hiti, L. Kazdova Transpulmonary B-type natriuretic peptide uptake and cyclic guanosine monophosphate release in heart failure and pulmonary hypertension: the effects of sildenafil J Am Coll Cardiol 54 2009 595 600
10. Z. Lu, X. Xu, X. Hu Oxidative stress regulates left ventricular PDE5 expression in the failing heart Circulation 121 2010 1474 1483
11. J. Nagendran, S.L. Archer, D. Soliman Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility Circulation 116 2007 238 248 (Pubitemid 47196559)
12. V.Q. Chau, F.N. Salloum, N.N. Hoke, A. Abbate, R.C. Kukreja Mitigation of the progression of heart failure with sildenafil involves inhibition of RhoA/Rho-kinase pathway Am J Physiol Heart Circ Physiol 300 2011 H2272 H2279
13. M. Zhang, E. Takimoto, S. Hsu Myocardial remodeling is controlled by myocyte-targeted gene regulation of phosphodiesterase type 5 J Am Coll Cardiol 56 2010 2021 2030
14. E. Takimoto, H.C. Champion, M. Li Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy Nat Med 11 2005 214 222 (Pubitemid 40321358)
15. S.D. Katz, K. Balidemaj, S. Homma, H. Wu, J. Wang, S. Maybaum Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure J Am Coll Cardiol 36 2000 845 851
16. P.W. Fisher, F. Salloum, A. Das, H. Hyder, R.C. Kukreja Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity Circulation 111 2005 1601 1610 (Pubitemid 40525159)
17. S. Koka, A. Das, S.G. Zhu Long-acting phosphodiesterase-5 inhibitor tadalafil attenuates doxorubicin-induced cardiomyopathy without interfering with chemotherapeutic effect J Pharmacol Exp Ther 334 2010 1023 1030
18. R.C. Kukreja, F. Salloum, A. Das Pharmacological preconditioning with sildenafil: basic mechanisms and clinical implications Vascul Pharmacol 42 2005 219 232 (Pubitemid 40726325)
19. F.N. Salloum, A. Abbate, A. Das Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice Am J Physiol Heart Circ Physiol 294 2008 H1398 H1406
20. S. Rosanio, Y. Ye, S. Atar Enhanced cardioprotection against ischemia-reperfusion injury with combining sildenafil with low-dose atorvastatin Cardiovasc Drugs Ther 20 2006 27 36
21. R. Ockaili, F. Salloum, J. Hawkins, R.C. Kukreja Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits Am J Physiol Heart Circ Physiol 283 2002 H1263 H1269
22. X. Wang, P.W. Fisher, L. Xi, R.C. Kukreja Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection J Mol Cell Cardiol 44 2008 105 113
23. N. Ahmad, Y. Wang, A.K. Ali, M. Ashraf Long-acting phosphodiesterase-5 inhibitor, tadalafil, induces sustained cardioprotection against lethal ischemic injury Am J Physiol Heart Circ Physiol 297 2009 H387 H391
24. F.N. Salloum, R.A. Ockaili, M. Wittkamp, V.R. Marwaha, R.C. Kukreja Vardenafil: a novel type 5 phosphodiesterase inhibitor reduces myocardial infarct size following ischemia/reperfusion injury via opening of mitochondrial K(ATP) channels in rabbits J Mol Cell Cardiol 40 2006 405 411 (Pubitemid 43277842)
25. M. Jamnicki-Abegg, D. Weihrauch, P.C. Chiari Diabetes abolishes sildenafil-induced cGMP-dependent protein kinase-I expression and cardioprotection J Cardiovasc Pharmacol 50 2007 670 676 (Pubitemid 350307037)
26. M. Madhani, A.R. Hall, F. Cuello Phospholemman Ser69 phosphorylation contributes to sildenafil-induced cardioprotection against reperfusion injury Am J Physiol Heart Circ Physiol 299 2010 H827 H836
27. F.N. Salloum, V.Q. Chau, N.N. Hoke Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase g-dependent generation of hydrogen sulfide Circulation 120 Suppl 2009 S31 S36
28. C. Sesti, V. Florio, E.G. Johnson, R.A. Kloner The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size Int J Impot Res 19 2007 55 61 (Pubitemid 46067349)
29. G. Szabo, T. Radovits, G. Veres Vardenafil protects against myocardial and endothelial injuries after cardiopulmonary bypass Eur J Cardiothorac Surg 36 2009 657 664
30. T. Reffelmann, R.A. Kloner Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation Cardiovasc Res 59 2003 441 449 (Pubitemid 37272038)
31. T. Swallow, C. Anderson Phosphodiesterase-5 inhibitors help climbers to achieve new heights BJU Int 97 2006 672 673 (Pubitemid 43383490)
32. A. Wright, S. Brearey, C. Imray High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high-altitude cerebral and pulmonary oedema Expert Opin Pharmacother 9 2008 119 127 (Pubitemid 351233753)
33. X.Q. Xu, Z.C. Jing High-altitude pulmonary hypertension Eur Respir Rev 18 2009 13 17
34. M. Maggiorini, H.P. Brunner-La Rocca, S. Peth Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial Ann Intern Med 145 2006 497 506. (Pubitemid 46780953)
35. M. Fischler, M. Maggiorini, L. Dorschner Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema Am J Respir Crit Care Med 180 2009 346 352
36. L. Zhao, N.A. Mason, N.W. Morrell Sildenafil inhibits hypoxia-induced pulmonary hypertension Circulation 104 2001 424 428 (Pubitemid 32678272)
37. A.R. Hsu, K.E. Barnholt, N.K. Grundmann, J.H. Lin, S.W. McCallum, A.L. Friedlander Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia J Appl Physiol 100 2006 2031 2040 (Pubitemid 43845879)
38. H.A. Ghofrani, F. Reichenberger, M.G. Kohstall Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial Ann Intern Med 141 2004 169 177
39. A.A. Aldashev, B.K. Kojonazarov, T.A. Amatov Phosphodiesterase type 5 and high altitude pulmonary hypertension Thorax 60 2005 683 687 (Pubitemid 41129068)
40. B. Tantini, A. Manes, E. Fiumana Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells Basic Res Cardiol 100 2005 131 138 (Pubitemid 40361605)
41. J.J. Oliver, V.P. Melville, D.J. Webb Effect of regular phosphodiesterase type 5 inhibition in hypertension Hypertension 48 2006 622 627 (Pubitemid 44843865)
42. G. Jackson, N. Benjamin, N. Jackson, M.J. Allen Effects of sildenafil citrate on human hemodynamics Am J Cardiol 83 Suppl 1999 13C 20C (Pubitemid 29122753)
43. R.A. Kloner, M. Mitchell, J.T. Emmick Cardiovascular effects of tadalafil Am J Cardiol 92 Suppl 2003 37M 46M (Pubitemid 37386274)
44. J.J. Oliver, J.W. Dear, D.J. Webb Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension Hypertension 56 2010 62 67
45. E. Caglayan, M. Huntgeburth, T. Karasch Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease Arch Intern Med 166 2006 231 233 (Pubitemid 43144949)
46. R. Fries, K. Shariat, H.Böhm M. von Wilmowsky Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy Circulation 112 2005 2980 2985 (Pubitemid 41612301)
47. C.S. Brueckner, M.O. Becker, T. Kroencke Effect of sildenafil on digital ulcers in systemic sclerosis: analysis from a single centre pilot study Ann Rheum Dis 69 2010 1475 1478
48. E.A. Friedman, P.A. Harris, A.J. Wood, C.M. Stein, D. Kurnik The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon Clin Pharmacol Ther 81 2007 503 509 (Pubitemid 46452307)
49. E. Schiopu, V.M. Hsu, A.J. Impens Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis J Rheumatol 36 2009 2264 2268
50. A.L. Herrick, F. van den Hoogen, A. Gabrielli Modified-release sildenafil reduces Raynaud's attack frequency in limited cutaneous systemic sclerosis Arthritis Rheum 63 2011 775 782
51. J.W. Downing, R. Ramasubramanian, R.F. Johnson Hypothesis: selective phosphodiesterase-5 inhibition improves outcome in preeclampsia Med Hypotheses 63 2004 1057 1064 (Pubitemid 39422408)
52. E. Fung, R.R. Fiscus, A.P. Yim, G.D. Angelini, A.A. Arifi The potential use of type-5 phosphodiesterase inhibitors in coronary artery bypass graft surgery Chest 128 2005 3065 3073 (Pubitemid 41507668)
53. A. Senthilkumar, R.D. Smith, J. Khitha Sildenafil promotes ischemia-induced angiogenesis through a PKG-dependent pathway Arterioscler Thromb Vasc Biol 27 2007 1947 1954 (Pubitemid 47312303)
54. M. Sahara, M. Sata, T. Morita, T. Nakajima, Y. Hirata, R. Nagai A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway Arterioscler Thromb Vasc Biol 30 2010 1315 1324